Summary
The goal of the proposed funding announcement is twofold, to promote preclinical and patient based studies examining the mechanism(s) through which incretin mimetics (including agonists or antagonists of GLP-1, GIP-1, or dual GLP-1/GIP-1 agents) impact cancer risk, and to draw talented scientists who understand the dynamic changes caused by these agents to investigate the mechanisms of how these agents influence cancer risk rather than shorter term outcomes such as weight loss and diabetes. The data thus far suggests that these agents may increase the risk of some, while decreasing the risk of other obesity related cancers.
Eligibility
- Nonprofits Non Higher Education Without 501c3
- County Governments
- Small Businesses
- Independent School Districts
- Other
- Public and State Institutions of Higher Education
- State Governments
- Nonprofits Having A 501(c)(3) Status With the Irs Other Than Institutions of Higher Education
- Public and Indian Housing Authorities
- City Or Township Governments
- Native American Tribal Organizations Other Than Federally Recognized Tribal Governments
- Private Institutions of Higher Education
- For Profit Organizations Other Than Small Businesses
- Special District Governments
- Native American Tribal Governments Federally Recognized
Funding categories
- Education
- Health
Official source and attribution
This directory republishes federal opportunity information sourced from Simpler.Grants.gov and Grants.gov. Local Business Ranks is not affiliated with or endorsed by the federal government. Always rely on the official opportunity record for application requirements and changes.
Open the official federal record